Physician

Anthony J Magdalinski, DO

According to 2025 Medicare claims, Anthony Magdalinski, DO (NPI: 1528067352) practices medical oncology in the Montgomery County-Bucks County-Chester County, PA market, with the plurality of this provider's patient population coming from Montgomery, PA. This provider's primary affiliated billing organization is ALLIANCE CANCER SPECIALISTS P.C. (NPI: 1487923686; TIN: 452552343) and primary practice location at 18960-1560.

Magdalinski's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 758 traditional Medicare patients, billed 173,813 HCPCS/CPT codes, and received $3,212,323 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,899 prescription claims across 310 beneficiaries totaling $4,267,506 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 12 claims. Open Payments data shows 11 records totaling $250. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,722,026 to $4,267,506. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $2,335 to $1,689.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	810	157,284	$2,104,503
2016	830	201,515	$2,956,335
2017	829	214,807	$2,753,960
2018	816	256,208	$3,872,455
2019	820	223,918	$3,417,351
2020	795	259,272	$3,905,902
2021	751	239,109	$3,025,055
2022	689	239,557	$3,416,507
2023	704	219,492	$3,379,157
2024	758	173,813	$3,212,323

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	239	1,445	$1,722,026
2016	284	1,577	$2,390,412
2017	258	1,622	$3,091,307
2018	277	1,839	$3,416,894
2019	321	2,025	$4,130,804
2020	318	2,007	$4,470,897
2021	289	1,849	$4,897,117
2022	282	1,874	$5,192,481
2023	287	1,722	$4,252,192
2024	310	1,899	$4,267,506

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	65	$41,807
2016	N/R	77	$44,811
2017	N/R	50	$9,685
2018	N/R	91	$7,519
2019	N/R	13	$3,109
2020	N/R	81	$7,085
2021	N/R	38	$4,187
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	12	$207

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	319	632	$108
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	320	458	$72
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	97	107	$14
36415	Insertion of needle into vein for collection of blood sample	291	992	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	262	1,044	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	52	1,456	$814,008
Lenalidomide	Lenalidomide	50	1,295	$586,642
Jakafi	Ruxolitinib Phosphate	39	1,266	$536,145
Brukinsa	Zanubrutinib	28	840	$415,598
Lenvima	Lenvatinib Mesylate	11	330	$260,145

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$207

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	11	$250	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anthony J. Magdalinski, DO?

Tedicare shows public-source Medicare data for Anthony J. Magdalinski, DO (NPI 1528067352), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anthony J. Magdalinski, DO have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Anthony J. Magdalinski, DO?

Anthony J. Magdalinski, DO is linked to ALLIANCE CANCER SPECIALISTS P.C. (billing NPI 1487923686) in the available physician profile data.

Does Anthony J. Magdalinski, DO have Open Payments data?

Anthony J. Magdalinski, DO has 11 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.